Verastem, Inc. (2VSA.F)

EUR 4.28

(-35.15%)

Long Term Debt Summary of Verastem, Inc.

  • Verastem, Inc.'s latest annual long term debt in 2023 was 40.61 Million USD , up 56.24% from previous year.
  • Verastem, Inc.'s latest quarterly long term debt in 2024 Q2 was 35.39 Million USD , down -11.8% from previous quarter.
  • Verastem, Inc. reported annual long term debt of 25.99 Million USD in 2022, up 1048.23% from previous year.
  • Verastem, Inc. reported annual long term debt of 2.26 Million USD in 2021, down -89.7% from previous year.
  • Verastem, Inc. reported quarterly long term debt of 35.39 Million USD for 2024 Q2, down -11.8% from previous quarter.
  • Verastem, Inc. reported quarterly long term debt of 40.82 Million USD for 2023 Q1, up 57.04% from previous quarter.

Annual Long Term Debt Chart of Verastem, Inc. (2023 - 2011)

Historical Annual Long Term Debt of Verastem, Inc. (2023 - 2011)

Year Long Term Debt Long Term Debt Growth
2023 40.61 Million USD 56.24%
2022 25.99 Million USD 1048.23%
2021 2.26 Million USD -89.7%
2020 21.98 Million USD -79.48%
2019 107.11 Million USD -6.65%
2018 114.73 Million USD 673.79%
2017 14.82 Million USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%

Peer Long Term Debt Comparison of Verastem, Inc.

Name Long Term Debt Long Term Debt Difference
BioNTech SE 191 Million EUR 78.735%
CureVac N.V. 36.81 Million EUR -10.313%
Biotest Aktiengesellschaft 377.3 Million EUR 89.235%
Biotest Aktiengesellschaft 377.3 Million EUR 89.235%
BRAIN Biotech AG 25.19 Million EUR -61.219%
Formycon AG 7.81 Million EUR -419.718%
Heidelberg Pharma AG 70.4 Thousand EUR -57587.446%
Medigene AG 2.03 Million EUR -1894.892%